Some research has suggested that inhibiting the protein DPP-4, which is produced by the human body, could provide benefit to patients infected with COVID-19. Sitagliptin is a diabetes drug in the DPP-4 inhibitor class that has also shown anti-inflammatory and immunoregulatory effects. Researchers investigated whether sitagliptin could help treat hospitalized COVID patients with type 2 diabetes. Read more